← Back to Clinical Trials
Recruiting NCT06989216

NCT06989216 Multi-modal Quantitative Imaging of the Skin

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06989216
Status Recruiting
Phase
Sponsor HJN Sverige AB/Neko Health
Condition Skin Cancer
Study Type OBSERVATIONAL
Enrollment 8,000 participants
Start Date 2023-02-01
Primary Completion 2026-02-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 8,000 participants in total. It began in 2023-02-01 with a primary completion date of 2026-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.

Eligibility Criteria

Inclusion criteria: * Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation. * Patients with signed informed consent Exclusion criteria: * Cognitive impairment * Patients unable to understand the oral and written study information in Swedish or English * Other severe disorder or terminal disease * Patients unable to provide an informed consent * Patients not able to keep balance, while standing up with closed eyes, without any aid * Claustrophobic patients

Contact & Investigator

Central Contact

Mattias Windå, MSc

✉ mattias@nekohealth.com

📞 0703169040

Principal Investigator

Andreea Valdman, MD

PRINCIPAL INVESTIGATOR

Neko Health AB

Frequently Asked Questions

Who can join the NCT06989216 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Skin Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06989216 currently recruiting?

Yes, NCT06989216 is actively recruiting participants. Contact the research team at mattias@nekohealth.com for enrollment information.

Where is the NCT06989216 trial being conducted?

This trial is being conducted at Stockholm, Sweden, Stockholm, Sweden, Stockholm, Sweden.

Who is sponsoring the NCT06989216 clinical trial?

NCT06989216 is sponsored by HJN Sverige AB/Neko Health. The principal investigator is Andreea Valdman, MD at Neko Health AB. The trial plans to enroll 8,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology